Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw ...

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

While RSV isn’t any more virulent than the cold, flu or COVID, the same precautions are recommended in order to control its ...

The estimated effectiveness of the respiratory syncytial virus (RSV) among older US veterans in the 2023-2024 respiratory ...

Among adults aged 75 and older, RSV was linked to a substantial burden of hospitalizations, ICU admissions, and in-hospital deaths before vaccines were available.

The U.S. is seeing a "quad-demic" as cases of COVID-19, flu, RSV and norovirus spread at the same time. Experts said this is ...

Vulnerable and elderly Australians are missing out on protection against respiratory syncytial virus (RSV) because many can’t afford to pay $350 for a one-off vaccine.

U.S. surges of COVID-19, influenza, respiratory syncytial virus (RSV) and norovirus have collectively been dubbed a ...

More than 86,000 recorded cases of respiratory syncytial virus in 2024 were in children younger than four years old.

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

UPMC saw an increase in RSV cases in its health system, including in Lancaster County, a spokesperson said Jan. 7, especially ...

Alone and in combination with other lower respiratory tract disease signs and symptoms, dyspnea is the best predictor of severe RSV outcomes.